ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Cincinnati, OH, USA:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Cincinnati, Ohio, United States and 66 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Cincinnati, Ohio, United States of America and 29 other locations

ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non...

Enrolling
Mature B-Cell Non-Hodgkin Lymphoma
Drug: Ifosfamide
Drug: Rituximab

Phase 1, Phase 2

Roche
Roche

Cincinnati, Ohio, United States and 21 other locations

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targ...

Enrolling
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Drug: IMPT-314

Phase 1, Phase 2

ImmPACT Bio

Cincinnati, Ohio, United States and 19 other locations

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participant...

Enrolling
Aggressive Non-Hodgkin Lymphoma
Indolent Non-Hodgkin Lymphoma
Drug: Lymphodepleting Chemotherapy
Biological: IL-2

Phase 1

Century Therapeutics

Cincinnati, Ohio, United States and 13 other locations

The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma...

Enrolling
Non-hodgkin Lymphoma
Drug: Epcoritamab

Phase 1

Genmab
Genmab

Cincinnati, Ohio, United States and 39 other locations

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Celgene
Celgene

Cincinnati, Ohio, United States and 125 other locations

Locations recently updated

safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Mosunetuzumab (Cohorts A-C)
Drug: Mosunetuzumab (Cohorts D-E)

Phase 2

Genentech
Genentech

Cincinnati, Ohio, United States and 57 other locations

This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a...

Enrolling
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: ONO-7018

Phase 1

Ono Pharmaceuticals
Ono Pharmaceuticals

Cincinnati, Ohio, United States and 9 other locations

(MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non...

Active, not recruiting
Neoplasms
Drug: VIP152 (BAY 1251152) 30 mg
Drug: VIP152 (BAY 1251152) 15 mg

Phase 1

Vincerx Pharma

Cincinnati, Ohio, United States and 15 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems